Lonza (LONN.SW) stock price, revenue, and financials

Lonza market cap is CHF56.1 b, and annual revenue was CHF4.51 b in FY 2020

CHF56.1 B

LONN.SW Mkt cap, 22-Oct-2021

CHF2.5 B

Lonza Revenue H1, 2021
Lonza Gross profit (H1, 2021)1 B
Lonza Gross profit margin (H1, 2021), %41%
Lonza Net income (H1, 2021)321 M
Lonza EBITDA (H1, 2021)988 M
Lonza EBIT (H1, 2021)317 M
Lonza Cash, 30-Jun-2021501 M
Lonza EV59.2 B
Get notified regarding key financial metrics and revenue changes at LonzaLearn more
Banner background

Lonza Revenue

Lonza revenue was CHF4.51 b in FY, 2020 which is a 23.9% year over year decrease from the previous period.

Embed Graph

Lonza Revenue Breakdown

Embed Graph

Lonza revenue breakdown by business segment: 25.8% from Capsules & Health Ingredients, 48.0% from Biologics, 15.5% from Small Molecules and 10.8% from Cell & Gene

Lonza Income Statement

Annual

CHFFY, 2018FY, 2019FY, 2020

Revenue

5.5b5.9b4.5b

Revenue growth, %

9%7%(24%)

Cost of goods sold

3.4b3.7b2.7b

Gross profit

2.1b2.3b1.8b

Gross profit Margin, %

38%38%41%

Sales and marketing expense

344.0m235.0m

R&D expense

110.0m84.0m

General and administrative expense

732.0m610.0m

Operating expense total

1.3b1.3b989.0m

EBITDA

1.4b1.5b1.4b

EBITDA margin, %

26%26%31%

EBIT

842.0m972.0m901.0m

EBIT margin, %

15%16%20%

Interest expense

85.0m83.0m52.0m

Interest income

1.0m3.0m

Pre tax profit

807.0m849.0m803.0m

Income tax expense

148.0m86.0m71.0m

Net Income

563.0m646.0m871.0m

EPS

8.810.29.8

Half Year

CHFH1, 2019H1, 2020H1, 2021

Revenue

3.0b3.1b2.5b

Revenue growth, %

(48%)

Cost of goods sold

1.8b1.9b1.5b

Gross profit

1.1b1.2b1.0b

Gross profit Margin, %

39%40%41%

Operating expense total

639.0m605.0m726.0m

EBITDA

787.0m893.0m988.0m

EBITDA margin, %

26%29%39%

EBIT

509.0m618.0m317.0m

EBIT margin, %

17%20%12%

Pre tax profit

442.0m564.0m296.0m

Income tax expense

49.0m86.0m33.0m

Net Income

300.0m478.0m321.0m

EPS

5.36.44.3

Lonza Balance Sheet

Annual

CHFFY, 2018FY, 2019FY, 2020

Cash

461.0m505.0m495.0m

Accounts Receivable

692.0m715.0m

Prepaid Expenses

181.0m256.0m

Inventories

1.3b1.1b

Current Assets

3.5b3.0b

PP&E

3.2b3.6b

Goodwill

3.7b3.7b3.1b

Total Assets

13.9b13.8b14.4b

Accounts Payable

428.0m308.0m

Short-term debt

441.0m741.0m796.0m

Current Liabilities

2.4b2.6b3.1b

Long-term debt

3.6b2.8b2.8b

Non-Current Liabilities

5.3b4.6b4.4b

Total Debt

4.1b3.5b3.6b

Total Liabilities

7.6b7.3b7.5b

Common Stock

74.0m74.0m74.0m

Additional Paid-in Capital

3.3b3.3b2.8b

Retained Earnings

3.5b3.9b4.0b

Total Equity

6.3b6.6b6.9b

Debt to Equity Ratio

0.6 x0.5 x0.5 x

Debt to Assets Ratio

0.3 x0.3 x0.2 x

Financial Leverage

2.2 x2.1 x2.1 x

Half Year

CHFH1, 2019H1, 2020H1, 2021

Cash

413.0m552.0m501.0m

Current Assets

2.9b3.1b5.0b

Total Assets

13.5b13.9b15.2b

Short-term debt

637.0m330.0m858.0m

Current Liabilities

2.3b1.9b3.1b

Long-term debt

3.1b3.5b2.8b

Non-Current Liabilities

5.0b5.5b4.7b

Total Debt

3.8b3.8b3.6b

Total Liabilities

7.2b7.4b7.8b

Common Stock

74.0m74.0m74.0m

Additional Paid-in Capital

3.3b3.3b3.2b

Retained Earnings

3.5b4.0b4.1b

Total Equity

6.2b6.5b7.3b

Debt to Equity Ratio

0.6 x0.6 x0.5 x

Debt to Assets Ratio

0.3 x0.3 x0.2 x

Financial Leverage

2.2 x2.1 x2.1 x

Lonza Cash Flow

Annual

CHFFY, 2018FY, 2019FY, 2020

Net Income

563.0m646.0m871.0m

Depreciation and Amortization

526.0m526.0m

Accounts Receivable

(5.0m)(167.0m)

Inventories

(207.0m)(129.0m)

Accounts Payable

77.0m(38.0m)

Cash From Operating Activities

1.1b986.0m1.1b

Purchases of PP&E

(528.0m)(786.0m)(892.0m)

Cash From Investing Activities

(652.0m)(285.0m)(1.1b)

Long-term Borrowings

(340.0m)(1.9b)(850.0m)

Dividends Paid

(206.0m)(206.0m)(206.0m)

Cash From Financing Activities

(413.0m)(672.0m)93.0m

Net Change in Cash

3.0m23.0m114.0m

Interest Paid

82.0m49.0m

Income Taxes Paid

143.0m150.0m

Half Year

CHFH1, 2019H1, 2020H1, 2021

Net Income

30.0m478.0m321.0m

Cash From Operating Activities

166.0m434.0m549.0m

Purchases of PP&E

(308.0m)(416.0m)(516.0m)

Cash From Investing Activities

269.0m(470.0m)(435.0m)

Long-term Borrowings

(315.0m)(565.0m)(29.0m)

Dividends Paid

(206.0m)(207.0m)(225.0m)

Cash From Financing Activities

(502.0m)104.0m(201.0m)

Net Change in Cash

(69.0m)52.0m(74.0m)

Lonza Ratios

CHFFY, 2018

Revenue/Employee

366.3k

Debt/Equity

0.6 x

Debt/Assets

0.3 x

Financial Leverage

2.2 x

Lonza Operating Metrics

FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Manufacturing and R&D Facilities

40537055

Patent Families

650630575569

Countries

30303030

Clinical Development Programs (Pharma and Biotech)

350575730820

Commercial Medicines Supplied (Pharma and Biotech)

50290310245

Capsules Produced (Pharma and Biotech)

140 b200 b200 b230 b

Commercial Large-Molecule Medicines (Biologics)

22254045

Large-Molecule Clinical Development Programs (Biologics)

305380420

Clinical Small-Molecule Programs (Small-Molecule Businesses)

315270350400

Commercial Small-Molecule Programs (Small-Molecule Businesses)

205265270200

Customers (Specialty Ingredients)

12 k19 k5.3 k5.8 k

Customers (Consumer Health)

7 k7 k

Biocide Formulations (Coatings and Composites)

200200

Composite Resins Systems (Coatings and Composites)

3030

Customers (Agricultural Businesses)

4001 k

Products (Agricultural Businesses)

250250

Products (Water Care)

7401 k

Brands (Water Care)

2340

Brands

1 k800792

Customers (Microbial Control Solutions)

4.7 k

Customers (Specialty Chemical Services)

1.3 k

Trademarks and Trademark Applications

5.6 k5.28 k

Lonza Human Capital

Lonza's employees are reported to be approximately 33% female and 67% male.
FY, 2020FY, 2019FY, 2018
Male67%68.2%69.2%
Female32.4%31.8%30.8%
Other0.6%

Lonza Employee Rating

3.3846 votes
Culture & Values
3
Work/Life Balance
3
Senior Management
2.7
Salary & Benefits
3.4
Career Opportunities
3.1
Source